UNITED STATES SECURITIES AND EXCHANGE COMMISSION Form 144 Filer Information Washington, D.C. 20549

Form 144

FORM 144

NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933

144: Filer Information

Filer CIK 0001551891 Filer CCC XXXXXXXX Is this a LIVE or TEST Filing? LIVE TEST Submission Contact Information

Name Phone **E-Mail Address**

144: Issuer Information

Name of Issuer	ARS Pharmaceuticals, Inc.
SEC File Number	001-39756
Address of Issuer	11682 EL CAMINO REAL, SUITE 120 SAN DIEGO CALIFORNIA 92130
Phone	858-771-9307
Name of Person for Whose Account the Securities are To Be Sold	Shawver Laura
See the definition of "person" in personnel (a) of Dule 144 Information	n is to be given not only as to the nerson fo

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

Director

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value			Securities
Common	Merrill Lynch 101 S. Ellsworth Ave., 4th Floor San Mateo CA 94401	100000	720000.00	94403028	08/01/2023	Nasdaq

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

this

144: Securities To Be Sold

Title of the Class

Date you Nature of Acquired Acquisition Transaction Name of Person Is from Whom Acquired

Date Donor Acquired

Amount of Securities Acquired

Nature of Payment *

Date of

Payment

		a Gift?		
Common	08/01/2023 Stock Option Award Exercise	ARS Pharmaceuticals, 🕅 Inc.	18715	08/01/2023 Cash
Common	04/29/2020 Stock Option Award	ARS Pharmaceuticals, 🔲 Inc.	81285	04/29/2020 Cash Upon Exercise

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale Sold	Gross Proceeds
Laura Shawver 6638 Avenida De Las Pescas La Jolla CA 92037	Common	05/08/2023 57100	351917.52
Laura Shawver 6638 Avenida De Las Pescas La Jolla CA 92037	Common	05/09/2023 42900	227963.91
Laura Shawver 6638 Avenida De Las Pescas La Jolla CA 92037	Common	06/01/2023 73059	469858.26
Laura Shawver 6638 Avenida De Las Pescas La Jolla CA 92037	Common	06/02/2023 26941	187183.35
Laura Shawver 6638 Avenida De Las Pescas La Jolla CA 92037	Common	07/03/2023 26520	178343.73
Laura Shawver 6638 Avenida De Las Pescas La Jolla CA 92037	Common	07/05/2023 31112	199557.38
Laura Shawver 6638 Avenida De Las Pescas La Jolla CA 92037	Common	07/06/2023 33510	212551.06
Laura Shawver 6638 Avenida De Las Pescas La Jolla CA 92037	Common	07/07/2023 8858	56368.53

144: Remarks and Signature

Remarks	The nature of the payment will be cash for the Stock Option Award of 81,285 shares referenced in the Securities to be Sold section upon exercise.
Date of Notice	08/01/2023
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	08/15/2022
ATTENTION:	

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading

instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date. Signature Laura Shawver

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)